Getting bacteria to the sludge blanket

The problem the marketing skips

A treatment lagoon is a column of water, commonly six to fifteen feet of it, with the sludge blanket lying on the floor. A product broadcast across the surface has to travel the whole depth, survive the journey, and then stay in place at the bottom long enough to do useful work. That is the central engineering problem of the entire category, and it is much less studied than the marketing around it suggests. Most brochures describe what the organisms do once they are in the sludge; very few say anything measured about how many of them get there, or how quickly the rest are carried away.

Standard limnology sets the terms. An unmixed water body stratifies into layers of different temperature and density, and those density gradients limit the exchange of anything — heat, dissolved oxygen, suspended cells — between the surface and the bottom. A cell released at the top of a stratified lagoon may never reach the floor at all, so the column itself works against delivery rather than for it. Depth is not a detail here; it is the whole difficulty.

Three ways an introduced cell is lost

The peer-reviewed bioaugmentation literature is consistent about what becomes of cells that are freely suspended rather than protected, and three fates dominate. The first is washout: a lagoon is a flow-through system, and a cell that stays in suspension leaves with the effluent before it can settle and work. The second is predation by protozoa, which graze on introduced cells as readily as on any others. The third is competitive exclusion by the resident community — the established population already adapted to the lagoon, which holds every advantage over a newcomer. None of these is a formulation defect. They are the default outcome for a cell that is simply poured onto the water and left to find its own way down.

What the industry's hardware quietly admits

There is circumstantial evidence that the industry itself regards surface dosing as inadequate for bottom sludge. At least a dozen independent manufacturers have separately engineered dense sinking granules or carrier-based formats whose entire purpose is to place organisms down in the sludge layer rather than leave them drifting in the water column. When that many competitors, working independently over two decades, converge on the same answer, the convergence is worth something. But it is worth being precise about what: convergence is circumstantial evidence, not a controlled trial, and a whole industry can agree on an approach without any of its members having published the measurement that would actually settle the question.

Carrier immobilisation, and what it costs

The most studied answer to the washout-and-retention problem is immobilisation. A porous mineral carrier does two jobs at once: it is dense enough to transport the cells down into the sludge, and its internal structure gives them somewhere to lodge, so they are retained and partly shielded from washout and predation once they arrive. This is a recognised and genuinely researched strategy rather than a marketing conceit. The same literature is candid about the trade-offs, though. Carriers add cost, and immobilisation can reduce the metabolic activity of the organisms it protects, so a retained cell is not automatically a more productive one — the technique buys retention and pays for it in rate.

Even a sinking solid only reaches the interface

It is tempting to treat a sinking format as the solved version of the problem, and it is not. A dense solid descends and delivers its organisms to the sludge interface — the boundary where water meets the top of the blanket — rather than distributing them evenly through the blanket itself. Getting organisms to penetrate a dense, anaerobic sludge mass is an unsolved problem for every format on the market, this one included. Honesty on this point is part of the position: a sinking solid is a better answer to delivery than broadcasting a liquid across the surface, but better is not the same as solved, and no one selling into this category should pretend otherwise.

None of this is an argument against biological treatment. It is an argument for modest, specific claims, and for sizing an order against the lagoon in front of you rather than a figure from a brochure. A dose is not a number carried in anyone's head; it comes from the manufacturer's written dose table applied to your cell's depth, area and treatable fraction, which is what the dosing planner is for. Format matters, delivery matters, and the depth of your particular lagoon matters — which is exactly why the sizing has to start from your lagoon and not from ours.